Full Description
This textbook serves as a comprehensive reference on the latest science underlying the development of biological therapies, as well as their use in animal and human studies of rheumatological disease. Part A covers targets of emerging therapies - targeting/manipulating cells, targeting cell surface receptors, targeting cytokines, inflammatory mediators and transcription factors, and targeting plasma molecules. Part B then examines the use and implementation of these new therapies in the clinic, covering their use in treating specific rheumatological conditions. Part C discusses issues relating to study design and regulatory issues in the US and Europe.
Contents
Part A. Targets. Section IB-cells. Macrophages. Dendritic cells. Neutrophils. Fibroblasts. Mast Cells. Section II: Targeting Cell Surface Receptors. Complement Receptors. Fc-Receptors. CD-28. Fas. Section III: Targeting Cytokines. TNF-alpha. IL-1. IL-6. IL-18. IL-12. IL-15. Th1/Th2 balance a) Experimental models of rheumatological diseases b) Human disease. OPG. Chemokines. The balance between pro- and anti- inflammatory cytokines. Section IV. Targeting Inflammatory Mediators and Transcription Factors. iNOS. COX/PG synthases. Matrix molecules. NFkB. Jak/STATs. MMPs. Angiogenesis. Section V: Targeting. Immunoglobulins. Complement. Apheresis. Part B. Studies in Human and Experimental Rheumatic Diseases. Ethical Issues. Rheumatoid Arthritis. Biologics in Early Arthritis. Juvenile Arthritis. Psoriatic arthritis/psoriasis. Spondylarthritis. Systemic Lupus Erythematosus. Vasculitis. Myositis. Part C. Study Design. Randomized Controlled Trials. Long-Term Observational Studies. Long-Term Monitoring of Experimental (Novel) Therapies. Community-Based Studies. Regulatory Issues - FDA Index. Section II: Targeting Cell Surface Receptors. Section III: Targeting Cytokines. Section IV: Targeting Inflammatory mediators and Transcription Factors.
